At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 249 enrolled
Drug / intervention
USL255 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures
In Brief
A Phase 3 clinical trial evaluating USL255 and Placebo for Epilepsy. Completed, enrolled 249 participants across 69 sites in 16 countries.
Detailed Summary
The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesArgentina, Australia, Belgium, Canada, Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionDec 2012
Study CompletionJan 2013
TodayJul 2026
First PostedJun 11, 2010
Enrollment StartMay 1, 2010
Primary CompletionDec 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.1 years ago
Interventions
USL255drug
Placebodrug